Sinn Féin - On Your Side

Senator Conway-Walsh questions HSE on cost benefit analysis models

19 April, 2018 - by Rose Conway-Walsh

Mayo Sinn Féin Senator Rose Conway-Walsh has said that recent decisions regarding bed closures and withdrawal of medicines has undermined confidence among the public in the models of cost benefit analysis which underpin major HSE decisions.

Speaking at a meeting of the Health Committee, Senator Conway-Walsh said;

"Many decisions made by the HSE regarding bed closures and drug allocation have a huge impact on people’s lives. It is imperative that the process through which the HSE arrives at these decisions is transparent and logical. People need to see what considerations were taken into account in terms of short, medium and long term consequences.

"Regarding  the withdrawal of Versatis pain patches, it is very hard to see how a proper cost benefit analysis would have pointed towards denying so many people access to this medication. Already we are seeing the consequences of this decision in the short-term and long-term.

"The closure of district hospital beds, especially in rural Ireland, has already led to increased pressure on major hospitals such as Galway University Hospital. Add to this the pressure on patients to make long journeys and the decision to close local beds, it does not seem to have been thought through in the long term.

"Therefore I ask the HSE that decisions that have such widespread and long-term impacts be open to scrutiny and transparency."

Connect with Sinn Féin